TPOXX for PEP
Post-Exposure Prophylaxis for Smallpox
Key Facts
Indication
Post-Exposure Prophylaxis for Smallpox
Phase
Phase 3 / Development
Status
Active, in collaboration with U.S. Department of Defense
Company
About Siga
SIGA Technologies is a commercial-stage biopharmaceutical company with a critical mission to protect against high-consequence infectious disease threats, primarily orthopoxviruses. Its strategy is built on proactive preparedness and government partnerships, most successfully demonstrated by its lead product, TPOXX® (tecovirimat), which is a cornerstone of the U.S. Strategic National Stockpile and approved in multiple regions. The company has established a defensible niche in global health security, generating $139M in 2024 revenue through sales to over 30 countries, while advancing its pipeline into new indications and formulations.
View full company profile